Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04366518 · ClinicalTrials.gov registry record · Early Phase 1
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
A Early Phase 1 study of Psychosis and Hallucinations, Auditory, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT04366518: Recruiting Early Phase 1 study of Psychosis and Hallucinations, Auditory, sponsored by Yale University.
NCT04366518 is a Early Phase 1 study of Psychosis and Hallucinations, Auditory that is actively recruiting participants, run by Yale University. The registered enrollment target is 35 participants, below the 178-participant average among 35 other Psychosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04366518, a Early Phase 1 study of Psychosis and Hallucinations, Auditory, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.
Primary Outcome
Participants will perform the Conditioned Hallucinations task while in the scanner; the authors hypothesize that number of conditioned hallucinations exhibited during the task will be higher under placebo than physostigmine, but only in those who have high prior weighting on baseline assessment.
Conditions Studied
Interventions
- DRUG Placebo Patch
- DRUG Rivastigmine Transdermal System
- DRUG Scopolamine
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2032-08 |
| Phase | Early Phase 1 |
What NCT04366518 shows while recruiting
NCT04366518 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 178-participant average among 35 other Psychosis trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Psychosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo Patch is the first listed.
NCT04366518 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04366518 about?
NCT04366518 is a clinical study titled "Toward a Computationally-Informed, Personalized Treatment for Hallucinations". Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinat...
What is the current status of trial NCT04366518?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2021-07-15. Estimated completion is 2032-08.
What conditions does trial NCT04366518 study?
This clinical trial studies the following conditions: Psychosis, Hallucinations, Auditory.
What interventions are being tested in trial NCT04366518?
The interventions under investigation include: Placebo Patch (DRUG), Rivastigmine Transdermal System (DRUG), Scopolamine (DRUG).
Who is sponsoring clinical trial NCT04366518?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04366518 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04366518's enrollment target sits among peer trials
35 29th of 35 higher than 7 of 35 other Psychosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
ACTIVE NOT RECRUITING · Early Phase 1
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Determining the Role of Social Reward Learning in Social Anhedonia
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
RECRUITING · NA
-
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI